ReviewBMC medicine2022
WHO-led consensus statement on vaccine delivery costing: process, methods, and findings.
Review in BMC medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Costs of human papillomavirus vaccine delivery in low- and middle-income countries: A systematic review.Vaccine · 2024Pooled it
- Pooled it
- Costs and cost-effectiveness of influenza illness and vaccination in low- and middle-income countries: A systematic review from 2012 to 2022.PLoS medicine · 2024Pooled it
- Costs of managing adverse reactions to hexavalent vaccines: Comparison of DT3aP-HBV-IPV/Hib and DT2aP-HBV-IPV-Hib in France and Spain.Human vaccines & immunotherapeutics · 2026Article
- Maternal RSV vaccination to protect infants in Brazil: a model-based cost-effectiveness analysis for incorporation into the National Immunisation Program.Lancet regional health. Americas · 2026Article
- Service delivery costs of vaccination at health facilities in Guangzhou, China.Human vaccines & immunotherapeutics · 2025Article
- An Introduction to Costing and the Types of Costs Used within Health Economic Studies.PharmacoEconomics - open · 2025Review
- The cost of delivering COVID-19 vaccines in four districts in Malawi.Cost effectiveness and resource allocation : C/E · 2025Article
- The cost of delivering COVID-19 vaccines in Mozambique: a bottom-up costing study.BMC health services research · 2025Article
- Scoping Review of Current Costing Literature on Interventions to Reach Zero-Dose Children in Low- and Middle-Income Countries.Vaccines · 2024Article
- Cost of the typhoid conjugate vaccine introduction through an integrated campaign and follow-on routine immunization in Malawi.Vaccine: X · 2024Article
- Cost of delivering childhood RSV prevention interventions to the health system in Kenya: a prospective analysis.BMJ open · 2024Article
- Article
- Economic burden of measles outbreaks: a cost-of-illness study in a middle-income country in the post-elimination era.Revista panamericana de salud publica = Pan American journal of public health · 2024Article
- Article
- The Full Value of Vaccine Assessments (FVVA): a framework for assessing and communicating the value of vaccines for investment and introduction decision-making.BMC medicine · 2023Article
- Cost of introducing and delivering malaria vaccine (RTS,S/AS01BMJ global health · 2023Article
- Cost of introducing and delivering RTS,S/AS01 malaria vaccine within the malaria vaccine implementation program.Vaccine · 2023Article
- Voluntary Medical Male Circumcision to Reduce HIV Acquisition and Transmission.Current HIV/AIDS reports · 2022Review
- Costs of seasonal influenza vaccination in South Africa.Influenza and other respiratory viruses · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 8 institutions in 4 countries.
Funding
Abstract
backgroundDifferences in definitions and methodological approaches have hindered comparison and synthesis of economic evaluation results across multiple health domains, including immunization. At the request of the World Health Organization's (WHO) Immunization and Vaccines-related Implementation Research Advisory Committee (IVIR-AC), WHO convened an ad hoc Vaccine Delivery Costing Working Group, comprising experts from eight organizations working in immunization costing, to address a lack of standardization and gaps in definitions and methodological guidance. The aim of the Working Group was to develop a consensus statement harmonizing terminology and principles and to formulate recommendations for vaccine delivery costing for decision making. This paper discusses the process, findings of the review, and recommendations in the Consensus Statement.
methodsThe Working Group conducted several interviews, teleconferences, and one in-person meeting to identify groups working in vaccine delivery costing as well as existing guidance documents and costing tools, focusing on those for low- and middle-income country settings. They then reviewed the costing aims, perspectives, terms, methods, and principles in these documents. Consensus statement principles were drafted to align with the Global Health Cost Consortium costing guide as an agreed normative reference, and consensus definitions were drafted to reflect the predominant view across the documents reviewed.
resultsThe Working Group identified four major workstreams on vaccine delivery costing as well as nine guidance documents and eleven costing tools for immunization costing. They found that some terms and principles were commonly defined while others were specific to individual workstreams. Based on these findings and extensive consultation, recommendations to harmonize differences in terminology and principles were made.
conclusionsUse of standardized principles and definitions outlined in the Consensus Statement within the immunization delivery costing community of practice can facilitate interpretation of economic evidence by global, regional, and national decision makers. Improving methodological alignment and clarity in program costing of health services such as immunization is important to support evidence-based policies and optimal resource allocation. On the other hand, this review and Consensus Statement development process revealed the limitations of our ability to harmonize given that study designs will vary depending upon the policy question that is being addressed and the country context.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.